-
Maxygen Announces $10 Million Stock Repurchase Program
Tuesday, May 31, 2011 - 5:00pm | 150Maxygen, Inc. (Nasdaq: MAXY) today announced a stock repurchase program under which the company may purchase up to $10.0 million of its common stock through December 31, 2011. Since December 2009, Maxygen has repurchased approximately 10.0 million shares of its common stock at an aggregate cost of...
-
Poniard Pharmaceuticals Board of Directors Urges Shareholders to Vote FOR Reverse Stock Split Proposal
Tuesday, May 31, 2011 - 2:17pm | 150The Board of Directors of Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) announced today that it has sent a general reminder urging all shareholders, including individual shareholders, to vote "FOR" management's proposal to provide the Board authority to effect a reverse stock split of the Company's...
-
Capstone Therapeutics Signs Alliance With BiolineRx to Develop Chrysalin (TP508) in Acute Myocardial Infarction
Tuesday, May 31, 2011 - 2:01pm | 220Capstone Therapeutics (Nasdaq: CAPS) today announced a material transfer agreement with BiolineRx to develop Chrysalin (TP508) in pre-clinical models of acute myocardial infarction. The goal of these studies is to further demonstrate the potential cardiovascular benefit of TP508 in an additional...
-
Biotech and Pharma News; BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Safety Study
Tuesday, May 31, 2011 - 10:54am | 1324LINCOLNSHIRE, Ill. - May 31, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of...
-
Regeneron Pharmaceuticals Spiking
Tuesday, May 31, 2011 - 10:51am | 75Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) have been spiking in the last few minutes and are close to breaking new intra-day highs. The stock is currently trading 1.63% higher at $59.22. Regeneron has been very active in recent weeks and may provide short-term traders some opportunities...
-
Morning Market Losers
Tuesday, May 31, 2011 - 10:00am | 104Westmoreland Coal Company (NASDAQ: WLBPZ) shares moved down 39.03% to $18.20 at 9:55 am. WLBPZ's 52-week trading range is $18.20-$31.75. Valley National Bancorp (NASDAQ: VLYWW) shares dropped 17.18% to $2.65. Magellan Petroleum Corporation (NASDAQ: MPET) dipped 14.75% to $1.56. The Board of...
-
Benzinga's Top Pre-Market NASDAQ Losers
Tuesday, May 31, 2011 - 8:27am | 148Avago Technologies Limited (NASDAQ: AVGO) dipped 3.11% to $33.92 in the pre-market session. AVGO reported the sale of 25,000,000 ordinary shares by certain existing shareholders to Deutsche Bank Securities Inc, Barclays Capital Inc and Citi. RF Micro Devices Inc (NASDAQ: RFMD) dropped 1.14% to $6....
-
Benzinga's Top Pre-Market NASDAQ Gainers
Tuesday, May 31, 2011 - 8:12am | 160Optimer Pharmaceuticals Inc (NASDAQ: OPTR) shares advanced 7.86% to $14 in the pre-market session. OPTR reported that the US Food and Drug Administration (FDA) has approved its antibacterial drug Dificid to treat Clostridium difficile. The Medicines Company (NASDAQ: MDCO) shares advanced 4.24% to...
-
BioSante Pharmaceuticals Completes Enrollment in LibiGel Phase III Safety Study
Tuesday, May 31, 2011 - 7:58am | 177BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced completion of enrollment in its ongoing LibiGel Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder in...
-
Citi Comments on Amylin Pharmaceuticals Drugs Results
Tuesday, May 31, 2011 - 7:37am | 111Citi is commenting on drug results from Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). “GLP-1 TRx and NRx scrips (Byetta + Victoza) are up 1.6% and down 0.3% wk/wk, respectively,” Citi writes. “Overall the GLP-1 market has grown nicely since Victoza's launch as indicated by the 4 wk average (TRx +34...
-
Jefferies Maintains Buy on Incyte
Tuesday, May 31, 2011 - 7:14am | 84Jefferies is out with its report today on Incyte (NASDAQ: INCY), maintaining Buy. In a note to clients, Jefferies writes, "While there were no major presentations for INCY's INCB28050 at EULAR, we note positive feedback from rheumatologists and new incremental details from the ORAL Solo Phase 3...
-
YM BioSciences Announces Orphan Drug Designation for JAK1/JAK2 Inhibitor CYT387 in Europe
Tuesday, May 31, 2011 - 7:01am | 242YM BioSciences (NYSE: YMI) today announced that it has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation to its JAK1/JAK2 inhibitor, CYT387, for the treatment of primary myelofibrosis, post-...
-
Novovax: Long-term value in vaccines
Monday, May 30, 2011 - 8:00pm | 111by John McCamant, editor The Medical Technology Stock Letter New management team members at Novovax (NVAX) have the experiences and skill sets necessary to drive the company's vaccines to commercialization. We expect this to result in substantial creation of shareholder value for investors in this...
-
Novovax: Long-term value in vaccines
Monday, May 30, 2011 - 8:00pm | 111by John McCamant, editor The Medical Technology Stock Letter New management team members at Novovax (NVAX) have the experiences and skill sets necessary to drive the company's vaccines to commercialization. We expect this to result in substantial creation of shareholder value for investors in this...
-
Good looking charts on the long side
Friday, May 27, 2011 - 6:26pm | 1896( click to enlarge ) DISH Network Corp. (NASDAQ:DISH) finally broke out today but the volume was not as high as expected. Meanwhile, the stock closed near the highs of the day on Friday and further upside is expected to be seen next week. ( click to enlarge ) Oncothyreon Inc. (NASDAQ:ONTY...